Supernus Pharmaceuticals beat analysts’ revenue expectations by 12.2% last quarter, reporting revenues of $174.2 million, up 6% year on year. It was a very strong quarter for the company, ...

What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness ...

Supernus reported preliminary Q4 2021 earnings results on Feb. 28, 2022. Check out why I currently consider SUPN stock as a solid hold.

Supernus is pulling back after its strong post Q3, 2022 run. See why SUPN's Q4 earnings should be particularly interesting for shareholders.

Supernus Pharmaceuticals, Inc. Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to ...

Supernus reported preliminary data in 2018 showing that the drug met the study’s goal. Last December, Supernus also announced positive results from a Phase 3 study testing its ADHD drug in adults.

For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the ...

Supernus Pharmaceuticals sued Indian generic drugmaker Zydus Cadila and its U.S. subsidiary in Manhattan federal court on Friday for allegedly infringing 10 patents with its proposed generic of ...

Supernus Pharmaceuticals Inc said on Monday it would buy Adamas Pharmaceuticals Inc for about $400 million, to expand its roster of treatments for Parkinson's disease and reduce reliance on its ...

Deal adds Zurzuvae to Supernus' portfolio. Sage Therapeutics accepts $795M buyout from Supernus Pharmaceuticals, surpassing Biogen's offer. Washington Business Journal ...